Evercore ISI started coverage on shares of Axovant Sciences (NASDAQ:AXGT) in a research report sent to investors on Thursday morning, Benzinga’s Daily Ratings Newsletter reports. The brokerage issued an outperform rating on the stock.
A number of other research firms have also recently commented on AXGT. Chardan Capital upgraded shares of Axovant Sciences from a neutral rating to a buy rating and set a $4.00 price target on the stock in a report on Monday, March 11th. HC Wainwright reiterated a buy rating and set a $7.00 price target on shares of Axovant Sciences in a report on Tuesday, March 12th. JMP Securities reiterated an outperform rating and set a $6.00 price target (down previously from $8.00) on shares of Axovant Sciences in a report on Monday, March 11th. Zacks Investment Research upgraded shares of Axovant Sciences from a hold rating to a buy rating and set a $1.25 price target on the stock in a report on Wednesday, April 10th. Finally, Guggenheim began coverage on shares of Axovant Sciences in a report on Friday, February 15th. They set a buy rating and a $7.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating, The stock presently has an average rating of Buy and a consensus price target of $5.05.
Shares of NASDAQ AXGT opened at $1.08 on Thursday. Axovant Sciences has a fifty-two week low of $0.93 and a fifty-two week high of $6.59. The company has a market cap of $166.45 million, a price-to-earnings ratio of -0.52 and a beta of 1.33. The company has a quick ratio of 2.02, a current ratio of 2.02 and a debt-to-equity ratio of 1.24.
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel therapeutics in the fields of neurology and psychiatry. Its therapeutic focus are Parkinson’s Disease and Lewy Body Dementia. It operates through the following geographical sgements: United States, Switzerland, Bermuda, and Other.
Featured Article: Risk Tolerance
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.